Table 1 Patient characteristics for the study cohort, in total and stratified by gender
Total (n,%) | Female (n,%) | Male (n,%) | |
|---|---|---|---|
292 | 68 (23) | 224 (77) | |
Age | |||
40–68 | 103 (35) | 24 (36) | 79 (35) |
69–76 | 95 (33) | 20 (29) | 75 (34) |
77–88 | 94 (32) | 24 (35) | 70 (31) |
Female | 68 (23) | ||
Male | 224 (77) | ||
Pathological stage | |||
pT1 | 39 (13) | 6 (8.8) | 33 (15) |
pT2a | 46 (16) | 9 (13) | 37 (17) |
pT2b | 27 (9,2) | 5 (7.4) | 22 (9.8) |
pT3a | 63 (23) | 13 (19) | 50 (22) |
pT3b | 83 (28) | 25 (37) | 58 (26) |
pT4a | 33 (11) | 10 (15) | 23 (10) |
pT4b | 1 (0.3) | 0 | 1 (0.4) |
Performed lymph node dissection | 256 (88) | 57 (84) | 199 (89) |
N0 | 170 (66) | 41 (72) | 129 (65) |
N1–3 | 86 (34) | 16 (28) | 70 (35) |
No lymph nodes dissected, median, IQR | 17 (11–17-22) | 16 (11–16-22) | 17 (11–17-22) |
Surgical resection margin status | |||
Positive surgical margins | 29 (10) | 6 (8.8) | 23 (10) |
CIS in urethral and/or ureteric margins | 8 (2.7) | 3 (4.4) | 5 (2.2) |
Histologic tumor type | |||
Urothelial carcinoma | 274 (94) | 61 (90) | 213 (95) |
Squamous cell carcinoma | 11 (3.8) | 5 (7.4) | 6 (2.7) |
Adenocarcinoma | 2 (0.7) | 1 (1.5) | 1 (0.4) |
Small cell neuroendocrine carcinoma | 5 (1.7) | 1 (1.5) | 4 (0.8) |
Divergent differentiation | 113 (41) | 31 (51) | 82 (39) |
Squamous | 61 (22) | 17 (28) | 44 (21) |
Micropapillary | 23 (8.4) | 4 6.6) | 19 (8.9) |
Glandular | 6 (2.2) | 1 (1.6) | 5 (2.3) |
Others/mixed | 23 (8.4) | 9 (15) | 14 (6.6) |
Concomitant carcinoma in situ | 136 (47) | 25 (37) | 111 (50) |
Tumor subsites | |||
Trigone ± ureteric orifices | 32 (11) | 9 (13) | 23 (10) |
Bladder neck | 49 (17) | 7 (10) | 42 (19) |
Diverticula | 12 (4.1) | 0 | 12 (5.4) |
Other | 199 (68) | 52 (77) | 147 (66) |
Chemotherapy | |||
Neoadjuvant | 47 (16) | 11 (16) | 36 (16) |
Adjuvant | 24 (8.2) | 4 (5.9) | 20 (8.9) |